There is an overlap in the tyrosine and L-dopa biosynthetic pathways, suggesting a common disease mechanism associated with PD and melanoma.
There is no evidence that levodopa contributes to the incidence or progression of melanoma.
Patients should receive regular screening for melanoma. Lack of patient and physician awareness can impede diagnoses.
Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Møller H. Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer. 2005;92(1):201-205.
Bertoni JM, Arlette JP, Fernandez HH, et al. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol. 2010;67(3):347-352.
Paisán-Ruiz, Houlden H. Common pathogenic pathways in melanoma and Parkinson disease. Neurology. 2010;75(18):1653-1655.